Developer docs
API playgroundTry for free, no card

Search company profiles

MC2 Therapeutics

Full company profile

uuid000ac43

Namestring
MC2 Therapeutics
Legal namestring
MC2 Therapeutics A/S
Company typeenum
Private
Founded yearint
2011
Descriptiontext

MC2 Therapeutics A/S is a private specialty pharmaceutical company headquartered in Hørsholm, Denmark, founded in 2011 (originally as MC2 Biotek and renamed in December 2016) and controlled by founding majority owner Mads Clausen. The company develops topical therapies for inflammatory skin conditions based on its proprietary PAD Technology™ platform—a formulation and drug delivery system that enables oil-in-water cream formulations with high penetration, solubility, and stability of active ingredients using only a fraction of the emulsifiers required by conventional creams. Its commercialized product, Wynzora® Cream (calcipotriene 0.005% and betamethasone dipropionate 0.064%), received FDA approval in July 2020 for plaque psoriasis, with subsequent EU decentralized procedure approval (first country July 2021), Australian TGA approval (November 2024), and Health Canada approval (November 2025); Phase III dosing in China began in January 2026. The pipeline includes MC2-25 (a first-in-class carbamylation inhibitor for CKD-associated pruritus and Vulvar Lichen Sclerosus), MC2-32 (an oral HSP90 inhibitor option-licensed from Regranion for Hidradenitis Suppurativa), MC2-03 (ciclosporin 0.06% ophthalmic formulation for dry eye disease), and the Biomee® dermo-cosmetics line.

The company operates a pure out-licensing business model: it retains product ownership, manufacturing, and supply responsibility while granting exclusive regional commercialization rights to established pharmaceutical partners in exchange for upfront payments, regulatory and sales milestone payments, and tiered double-digit royalties. Current licensees are EPI Health (US), Almirall (Europe, EUR 15M upfront in February 2021), Huadong Medicine (Greater China, USD 16M upfront plus USD 36M milestones in August 2023, expanded December 2025 to include Biomee®), Knight Therapeutics (Canada, Health Canada approval November 2025), Hyphens Pharma (ASEAN), and Actor Pharmaceuticals (Australia, TGA approval November 2024), collectively covering more than 40 countries across four continents. With 11–50 employees and wholly owned subsidiaries in the UK (Guildford) and US, MC2 serves dermatology patients (plaque psoriasis), nephrology/dialysis patients (CKD-aP), and underserved indications (VLS, HS) where few or no approved therapies exist, leveraging a leadership team with deep dermatology R&D and Big Pharma commercial credentials.

Short descriptiontext

MC2 Therapeutics is a private Danish specialty pharmaceutical company that develops topical therapies for inflammatory skin conditions using its proprietary PAD Technology™ platform, commercializing Wynzora® Cream for plaque psoriasis through regional licensing partners across 40+ countries and four continents.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersHørsholm, Denmark
HQ citystring
Hørsholm
HQ countrystring
Denmark
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
topical dermatology therapies, plaque psoriasis treatment, dermo-cosmetic products, transdermal drug delivery, inflammatory skin conditions
Industry5 codes
PRIMARYHLAIACAL
Dermatology Specialty Pharmaceuticals
SECONDARYHLAIAAAK
Dermatology & Aesthetics Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYCRABAAAF
Dermocosmetics & Medical-Grade Skincare
SECONDARYCRABAAAB
Treatment Skincare (Serums, Actives, Acne & Anti-aging)
SECONDARYCRADAMAF
Dermatology OTC & Skin Health (Acne Treatments, Eczema/Psoriasis OTC, Antifungals, Wart Removal)
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Health & Hygiene OTC Consumer Goods (First Aid, Oral Care, Personal Health)
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Perfumes, Cosmetics & Other Toilet Preparations2844
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Topical dermatology pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Product Licensing and Royalties
TypeLicensing Royalties
Description

MC2 Therapeutics licenses its commercialized products (Wynzora® Cream) to regional pharmaceutical partners in exchange for upfront payments, regulatory milestones, sales milestones, and tiered double-digit royalties. The company retains manufacturing and supply responsibilities while partners handle commercialization in their territories.

mc2therapeutics.com
2Dermo-cosmetic Product Sales
TypeHardware Sales
Description

The company manufactures and supplies its Biomee® dermo-cosmetic cream products (Biomee® Itch and Biomee® Dry Skin) to partners like Huadong for commercialization in their regions.

mc2therapeutics.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Wynzora
Description

Wynzora Cream - a cream-based fixed dose combination of calcipotriene and betamethasone dipropionate for topical treatment of plaque psoriasis, including scalp psoriasis. Enabled by PAD Technology.

mc2therapeutics.com
+2 more records
Core offering1 text field

MC2 Therapeutics develops, manufactures, and commercializes topical pharmaceutical therapies and dermo-cosmetics for inflammatory skin conditions, leveraging its proprietary PAD Technology™ single-phase aqueous cream platform. Its lead product is Wynzora® Cream, an FDA-approved fixed-dose combination of calcipotriene and betamethasone dipropionate for plaque psoriasis in adults, supplemented by dermo-cosmetic product lines (Biomee® Itch, Biomee® Dry Skin) and a development pipeline covering ophthalmology, uremic pruritus, venous leg ulcers, and chronic kidney disease–associated pruritus.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • PGA treatment success: 40.1% vs 24.0% for comparator (Taclonex®) in Phase 3 psoriasis trial
+3 more records
Product overview1 text field

MC2 Therapeutics is a private pharmaceutical company offering a portfolio of topical therapies and dermo-cosmetics for inflammatory skin conditions. The core product is Wynzora® Cream (FDA-approved 2020, EU-approved 2021), a fixed-dose combination of calcipotriene and betamethasone dipropionate for plaque psoriasis enabled by the proprietary PAD Technology™ platform. The company has expanded into dermo-cosmetics with the Biomee® line (Itch and Dry Skin creams), and maintains a pipeline of drug candidates including MC2-25 for CKD-associated pruritus, MC2-25 VLS for Vulvar Lichen Sclerosus, and MC2-32 for Hidradenitis Suppurativa, all leveraging PAD Technology™ or novel mechanisms of action.

Product and service4 records
1Wynzora® Cream
CategoryTopical dermatology pharmaceuticals
Description

Wynzora® Cream is a fixed-dose combination of calcipotriene and betamethasone dipropionate topical cream developed with PAD Technology™, indicated for the topical treatment of plaque psoriasis in adults 18 years of age and older. It is prescribed by dermatologists and commercialized through regional licensing partners in the U.S., EU, and other markets.

2Biomee® Itch
CategoryDermo-cosmetics
Description

Biomee® Itch is a consumer dermo-cosmetic skincare product in MC2's Biomee® line, formulated to address skin itching and irritation, leveraging the company's dermatology formulation expertise.

3Biomee® Dry Skin
CategoryDermo-cosmetics
Description

Biomee® Dry Skin is a consumer dermo-cosmetic skincare product in MC2's Biomee® line, formulated to moisturize and care for dry skin, leveraging the company's dermatology formulation expertise.

4MC2-03 PAD Eye Drop
CategoryOphthalmic pharmaceuticals
Description

MC2-03 PAD Eye Drop is an ophthalmic product developed with PAD Technology™, initially launched in the United Kingdom in 2012 as a Special product, representing one of MC2's first commercial applications of its topical delivery platform.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-01-05
Description

Agreement granting exclusive rights to commercialize Wynzora® Cream for treatment of plaque psoriasis in Australia. Wynzora® Cream was approved by TGA in November 2024 for topical treatment of mild to moderate plaque psoriasis on the body and scalp psoriasis in adults.

Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-11-14
Description

License and commercialization agreement for Wynzora® Cream in Canada. Knight Therapeutics obtained Health Canada approval in November 2025 for topical treatment of psoriasis vulgaris in adults and adolescents aged 12-17 years for up to 8 weeks.

Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-03-12
Description

License, supply and commercialization agreement for Wynzora® Cream in ASEAN countries.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-09-25
Description

Option to exclusively license RGRN-305 (now MC2-32) for all human indications globally, excluding Greater China. RGRN-305 is an orally administered HSP90 inhibitor for Hidradenitis Suppurativa and other immune-mediated inflammatory diseases. MC2 acquired global option rights in September 2023.

5Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (Huadong)
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-08-31
Description

License, development and commercialization agreement for Wynzora® Cream in Greater China (mainland China, Hong Kong, Macau, Taiwan). MC2 received USD 16 million upfront and is eligible for USD 36 million in sales milestones plus tiered double-digit royalties. Huadong is responsible for development and commercialization with oversight from a joint steering committee. In December 2025, the partnership expanded to include Biomee® Itch and Biomee® Dry Skin dermo-cosmetic products.

mc2therapeutics.com
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-02-17
Description

License, collaboration and commercialization agreement for European rights to Wynzora® Cream. MC2 received EUR 15 million upfront plus launch payments and is eligible for significant sales milestone payments and double-digit royalties. Almirall commercializes Wynzora® Cream in Europe while MC2 maintains responsibility for manufacturing and supply.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2020-08-24
Description

Collaboration agreement for US commercialization of WYNZORA® Cream. MC2 retains full ownership of the product. EPI Health utilizes its commercial infrastructure to promote and sell WYNZORA® Cream in return for a share of net sales.

8Moorfields Pharmaceuticals
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2011-07-08
Description

Collaboration and license agreement for development of novel ophthalmic products based on PAD Technology. Moorfields obtained exclusive rights to develop ophthalmic 'Specials' (unlicensed medicinal products) in UK and Ireland, while MC2 retained rights to develop licensed ophthalmic products.

mc2therapeutics.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Privately-held Danish specialty dermatology pharma with a leading psoriasis franchise (e.g., Enstilar®, Taclonex®/Dovobet®, Adtralza®). Directly comparable to MC2 as a European-headquartered dermatology-focused company commercializing topical and systemic psoriasis therapies.

2Maruho Co., Ltd.
TypeDirect peer
Description

Japan-based specialty dermatology pharmaceutical company with topical franchises for psoriasis and atopic dermatitis. Comparable as a regional specialty dermatology player leveraging topical formulation expertise.

TypeDirect peer
Description

US specialty dermatology company commercializing topical therapies for psoriasis (Zoryve® cream/foam) and atopic dermatitis. Direct peer as a small-cap, dermatology-focused company leveraging novel topical drug delivery and partnerships for global commercialization.

TypeEmerging player
Description

Belgian pharma with Cimzia® approved for Hidradenitis Suppurativa, directly competing with MC2-32. Emerging player overlap in the HS indication, with broader inflammation/immunology franchise.

TypeBroad incumbent
Description

Global pharma with dermatology presence following the Anacor acquisition. Also a potential strategic acquirer comparable in scale to typical MC2 exit paths; competes in inflammatory skin disease pipeline.

TypeBroad incumbent
Description

Global pharma with major dermatology franchise including Humira® (psoriasis), Skyrizi® (psoriasis), and Rinvoq® (atopic dermatitis). Broad incumbent competing against MC2's Wynzora® via newer IL-23 and JAK inhibitor franchises.

TypeDirect peer
Description

Roivant-affiliated dermatology company that developed Vtama® (tapinarof) for psoriasis and atopic dermatitis. Direct peer in the topical psoriasis space with comparable Phase 3-driven, partner-supported commercialization strategy.

TypeBroad incumbent
Description

Global dermatology-focused company across prescription (e.g., Epiduo®, Differin®, Soolantra®), aesthetics, and dermo-cosmetics. Broad incumbent comparable to MC2 across both prescription dermatology (Wynzora®) and dermo-cosmetic (Biomee®) lines.

TypeBroad incumbent
Description

Commercializes Opzelura® (ruxolitinib cream), a leading non-steroidal topical in atopic dermatitis and vitiligo. Broad incumbent overlapping with MC2's dermatology/topical focus, with substantially larger commercial resources.

TypeDirect peer
Description

Historical comp: small US dermatology-focused pharma acquired by Pfizer in 2016 for ~$5.2B. Closely comparable to MC2 in size, structure, and dermatology innovation model. (Acquirer Pfizer listed separately as broad incumbent.)

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

MC2 Therapeutics

Topical dermatology pharmaceuticalsmc2therapeutics.com

MC2 Therapeutics is a private Danish specialty pharmaceutical company that develops topical therapies for inflammatory skin conditions using its proprietary PAD Technology™ platform, commercializing Wynzora® Cream for plaque psoriasis through regional licensing partners across 40+ countries and four continents.

What MC2 Therapeutics does

MC2 Therapeutics A/S is a private specialty pharmaceutical company headquartered in Hørsholm, Denmark, founded in 2011 (originally as MC2 Biotek and renamed in December 2016) and controlled by founding majority owner Mads Clausen. The company develops topical therapies for inflammatory skin conditions based on its proprietary PAD Technology™ platform—a formulation and drug delivery system that enables oil-in-water cream formulations with high penetration, solubility, and stability of active ingredients using only a fraction of the emulsifiers required by conventional creams. Its commercialized product, Wynzora® Cream (calcipotriene 0.005% and betamethasone dipropionate 0.064%), received FDA approval in July 2020 for plaque psoriasis, with subsequent EU decentralized procedure approval (first country July 2021), Australian TGA approval (November 2024), and Health Canada approval (November 2025); Phase III dosing in China began in January 2026. The pipeline includes MC2-25 (a first-in-class carbamylation inhibitor for CKD-associated pruritus and Vulvar Lichen Sclerosus), MC2-32 (an oral HSP90 inhibitor option-licensed from Regranion for Hidradenitis Suppurativa), MC2-03 (ciclosporin 0.06% ophthalmic formulation for dry eye disease), and the Biomee® dermo-cosmetics line.

The company operates a pure out-licensing business model: it retains product ownership, manufacturing, and supply responsibility while granting exclusive regional commercialization rights to established pharmaceutical partners in exchange for upfront payments, regulatory and sales milestone payments, and tiered double-digit royalties. Current licensees are EPI Health (US), Almirall (Europe, EUR 15M upfront in February 2021), Huadong Medicine (Greater China, USD 16M upfront plus USD 36M milestones in August 2023, expanded December 2025 to include Biomee®), Knight Therapeutics (Canada, Health Canada approval November 2025), Hyphens Pharma (ASEAN), and Actor Pharmaceuticals (Australia, TGA approval November 2024), collectively covering more than 40 countries across four continents. With 11–50 employees and wholly owned subsidiaries in the UK (Guildford) and US, MC2 serves dermatology patients (plaque psoriasis), nephrology/dialysis patients (CKD-aP), and underserved indications (VLS, HS) where few or no approved therapies exist, leveraging a leadership team with deep dermatology R&D and Big Pharma commercial credentials.

MC2 Therapeutics firmographics

Firmographics
Name
MC2 Therapeutics
Legal name
MC2 Therapeutics A/S
Website
https://mc2therapeutics.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
11–50 employees
Short description
MC2 Therapeutics is a private Danish specialty pharmaceutical company that develops topical therapies for inflammatory skin conditions using its proprietary PAD Technology™ platform, commercializing Wynzora® Cream for plaque psoriasis through regional licensing partners across 40+ countries and four continents.
Ownership category
akta.pro rank

MC2 Therapeutics industry classification

Industry
Product category
Topical dermatology pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Perfumes, Cosmetics & Other Toilet Preparations (2844), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAIACAL
Dermatology Specialty Pharmaceuticals
SECONDARYHLAIAAAK
Dermatology & Aesthetics Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYCRABAAAF
Dermocosmetics & Medical-Grade Skincare
SECONDARYCRABAAAB
Treatment Skincare (Serums, Actives, Acne & Anti-aging)
SECONDARYCRADAMAF
Dermatology OTC & Skin Health (Acne Treatments, Eczema/Psoriasis OTC, Antifungals, Wart Removal)
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Health & Hygiene OTC Consumer Goods (First Aid, Oral Care, Personal Health)

Keywords

  • Topical dermatology therapies
  • Plaque psoriasis treatment
  • Dermo-cosmetic products
  • Transdermal drug delivery
  • Inflammatory skin conditions

Where MC2 Therapeutics is headquartered

Location

Headquarters

HQ city
Hørsholm
HQ country
Denmark
HQ region
Europe

Offices2 records

Markets served

MC2 Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Product Licensing and Royalties: MC2 Therapeutics licenses its commercialized products (Wynzora® Cream) to regional pharmaceutical partners in exchange for upfront payments, regulatory milestones, sales milestones, and tiered double-digit royalties. The company retains manufacturing and supply responsibilities while partners handle commercialization in their territories.
  2. Dermo-cosmetic Product Sales: The company manufactures and supplies its Biomee® dermo-cosmetic cream products (Biomee® Itch and Biomee® Dry Skin) to partners like Huadong for commercialization in their regions.

Go-to-market motion1 record

Distribution channels6 records

Marketing channels3 records

MC2 Therapeutics product offering

Product offering

Core offering

MC2 Therapeutics develops, manufactures, and commercializes topical pharmaceutical therapies and dermo-cosmetics for inflammatory skin conditions, leveraging its proprietary PAD Technology™ single-phase aqueous cream platform. Its lead product is Wynzora® Cream, an FDA-approved fixed-dose combination of calcipotriene and betamethasone dipropionate for plaque psoriasis in adults, supplemented by dermo-cosmetic product lines (Biomee® Itch, Biomee® Dry Skin) and a development pipeline covering ophthalmology, uremic pruritus, venous leg ulcers, and chronic kidney disease–associated pruritus.

Product overview

MC2 Therapeutics is a private pharmaceutical company offering a portfolio of topical therapies and dermo-cosmetics for inflammatory skin conditions. The core product is Wynzora® Cream (FDA-approved 2020, EU-approved 2021), a fixed-dose combination of calcipotriene and betamethasone dipropionate for plaque psoriasis enabled by the proprietary PAD Technology™ platform. The company has expanded into dermo-cosmetics with the Biomee® line (Itch and Dry Skin creams), and maintains a pipeline of drug candidates including MC2-25 for CKD-associated pruritus, MC2-25 VLS for Vulvar Lichen Sclerosus, and MC2-32 for Hidradenitis Suppurativa, all leveraging PAD Technology™ or novel mechanisms of action.

Differentiator

Problem solved

Functional benefit

Brands

  • Wynzora: Wynzora Cream - a cream-based fixed dose combination of calcipotriene and betamethasone dipropionate for topical treatment of plaque psoriasis, including scalp psoriasis. Enabled by PAD Technology.
  • Biomee
  • PAD Technology

Products and services

  • Wynzora® Cream Wynzora® Cream is a fixed-dose combination of calcipotriene and betamethasone dipropionate topical cream developed with PAD Technology™, indicated for the topical treatment of plaque psoriasis in adults 18 years of age and older. It is prescribed by dermatologists and commercialized through regional licensing partners in the U.S., EU, and other markets.
  • Biomee® Itch Biomee® Itch is a consumer dermo-cosmetic skincare product in MC2's Biomee® line, formulated to address skin itching and irritation, leveraging the company's dermatology formulation expertise.
  • Biomee® Dry Skin Biomee® Dry Skin is a consumer dermo-cosmetic skincare product in MC2's Biomee® line, formulated to moisturize and care for dry skin, leveraging the company's dermatology formulation expertise.
  • MC2-03 PAD Eye Drop MC2-03 PAD Eye Drop is an ophthalmic product developed with PAD Technology™, initially launched in the United Kingdom in 2012 as a Special product, representing one of MC2's first commercial applications of its topical delivery platform.

Quantifiable outcome

  • PGA treatment success: 40.1% vs 24.0% for comparator (Taclonex®) in Phase 3 psoriasis trial
  • +3 more outcomes

Companies that use MC2 Therapeutics

Customer profile

Named customers6 records

Segments4 records

Ideal customer profiles3 records

MC2 Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

MC2 Therapeutics partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered major, core and minor.

  • Actor Pharmaceuticals Pty LtdmajorChannel Partner/ Reseller/ Distributor · 5 January 2026Agreement granting exclusive rights to commercialize Wynzora® Cream for treatment of plaque psoriasis in Australia. Wynzora® Cream was approved by TGA in November 2024 for topical treatment of mild to moderate plaque psoriasis on the body and scalp psoriasis in adults.
  • Knight Therapeutics Inc.majorChannel Partner/ Reseller/ Distributor · 14 November 2024License and commercialization agreement for Wynzora® Cream in Canada. Knight Therapeutics obtained Health Canada approval in November 2025 for topical treatment of psoriasis vulgaris in adults and adolescents aged 12-17 years for up to 8 weeks.
  • Hyphens Pharma Pte. Ltd.majorChannel Partner/ Reseller/ Distributor · 12 March 2024License, supply and commercialization agreement for Wynzora® Cream in ASEAN countries.
  • Regranion, LLCcoreStrategic or Co-development Partner · 25 September 2023Option to exclusively license RGRN-305 (now MC2-32) for all human indications globally, excluding Greater China. RGRN-305 is an orally administered HSP90 inhibitor for Hidradenitis Suppurativa and other immune-mediated inflammatory diseases. MC2 acquired global option rights in September 2023.
  • Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (Huadong)coreChannel Partner/ Reseller/ Distributor · 31 August 2023License, development and commercialization agreement for Wynzora® Cream in Greater China (mainland China, Hong Kong, Macau, Taiwan). MC2 received USD 16 million upfront and is eligible for USD 36 million in sales milestones plus tiered double-digit royalties. Huadong is responsible for development and commercialization with oversight from a joint steering committee. In December 2025, the partnership expanded to include Biomee® Itch and Biomee® Dry Skin dermo-cosmetic products.
  • Almirall S.A.coreChannel Partner/ Reseller/ Distributor · 17 February 2021License, collaboration and commercialization agreement for European rights to Wynzora® Cream. MC2 received EUR 15 million upfront plus launch payments and is eligible for significant sales milestone payments and double-digit royalties. Almirall commercializes Wynzora® Cream in Europe while MC2 maintains responsibility for manufacturing and supply.
  • EPI Health, LLCcoreChannel Partner/ Reseller/ Distributor · 24 August 2020Collaboration agreement for US commercialization of WYNZORA® Cream. MC2 retains full ownership of the product. EPI Health utilizes its commercial infrastructure to promote and sell WYNZORA® Cream in return for a share of net sales.
  • Moorfields PharmaceuticalsminorStrategic or Co-development Partner · 8 July 2011Collaboration and license agreement for development of novel ophthalmic products based on PAD Technology. Moorfields obtained exclusive rights to develop ophthalmic 'Specials' (unlicensed medicinal products) in UK and Ireland, while MC2 retained rights to develop licensed ophthalmic products.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

MC2 Therapeutics competitors and assessment

Company assessment

Direct peers

  • LEO Pharma: Privately-held Danish specialty dermatology pharma with a leading psoriasis franchise (e.g., Enstilar®, Taclonex®/Dovobet®, Adtralza®). Directly comparable to MC2 as a European-headquartered dermatology-focused company commercializing topical and systemic psoriasis therapies.
  • Maruho Co., Ltd. Japan-based specialty dermatology pharmaceutical company with topical franchises for psoriasis and atopic dermatitis. Comparable as a regional specialty dermatology player leveraging topical formulation expertise.
  • Arcutis Biotherapeutics: US specialty dermatology company commercializing topical therapies for psoriasis (Zoryve® cream/foam) and atopic dermatitis. Direct peer as a small-cap, dermatology-focused company leveraging novel topical drug delivery and partnerships for global commercialization.
  • Dermavant Sciences: Roivant-affiliated dermatology company that developed Vtama® (tapinarof) for psoriasis and atopic dermatitis. Direct peer in the topical psoriasis space with comparable Phase 3-driven, partner-supported commercialization strategy.
  • Anacor Pharmaceuticals: Historical comp: small US dermatology-focused pharma acquired by Pfizer in 2016 for ~$5.2B. Closely comparable to MC2 in size, structure, and dermatology innovation model. (Acquirer Pfizer listed separately as broad incumbent.)

Emerging players

  • UCB: Belgian pharma with Cimzia® approved for Hidradenitis Suppurativa, directly competing with MC2-32. Emerging player overlap in the HS indication, with broader inflammation/immunology franchise.

Broad incumbents

  • Pfizer: Global pharma with dermatology presence following the Anacor acquisition. Also a potential strategic acquirer comparable in scale to typical MC2 exit paths; competes in inflammatory skin disease pipeline.
  • AbbVie: Global pharma with major dermatology franchise including Humira® (psoriasis), Skyrizi® (psoriasis), and Rinvoq® (atopic dermatitis). Broad incumbent competing against MC2's Wynzora® via newer IL-23 and JAK inhibitor franchises.
  • Galderma: Global dermatology-focused company across prescription (e.g., Epiduo®, Differin®, Soolantra®), aesthetics, and dermo-cosmetics. Broad incumbent comparable to MC2 across both prescription dermatology (Wynzora®) and dermo-cosmetic (Biomee®) lines.
  • Incyte Corporation: Commercializes Opzelura® (ruxolitinib cream), a leading non-steroidal topical in atopic dermatitis and vitiligo. Broad incumbent overlapping with MC2's dermatology/topical focus, with substantially larger commercial resources.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

MC2 Therapeutics social profiles

Digital presence

MC2 Therapeutics compliance and trust

Trust signal

Compliance1 record

MC2 Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

MC2 Therapeutics leadership team

Management profile

Number of profiles

Profiles8 records

MC2 Therapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

MC2 Therapeutics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

MC2 Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MC2 Therapeutics

What does MC2 Therapeutics do?

MC2 Therapeutics develops, manufactures, and commercializes topical pharmaceutical therapies and dermo-cosmetics for inflammatory skin conditions, leveraging its proprietary PAD Technology™ single-phase aqueous cream platform. Its lead product is Wynzora® Cream, an FDA-approved fixed-dose combination of calcipotriene and betamethasone dipropionate for plaque psoriasis in adults, supplemented by dermo-cosmetic product lines (Biomee® Itch, Biomee® Dry Skin) and a development pipeline covering ophthalmology, uremic pruritus, venous leg ulcers, and chronic kidney disease–associated pruritus.

Is MC2 Therapeutics a public or private company?

MC2 Therapeutics is a private company. It is classified as family owned and is currently operating.

When was MC2 Therapeutics founded?

MC2 Therapeutics was founded in 2011. It employs 11 to 50 people.

Where is MC2 Therapeutics based?

MC2 Therapeutics is headquartered in Hørsholm, Denmark, in the Europe region.

How does MC2 Therapeutics make money?

Two revenue lines are on record. Product Licensing and Royalties are the primary driver. The others are dermo-cosmetic Product Sales.

Who are MC2 Therapeutics's main competitors?

Direct peers on record are LEO Pharma, Maruho Co., Ltd., Arcutis Biotherapeutics, Dermavant Sciences and Anacor Pharmaceuticals. UCB is listed as an emerging player. Broad incumbents are Pfizer, AbbVie, Galderma and Incyte Corporation.

Does MC2 Therapeutics have an API?

No public API is recorded for MC2 Therapeutics.

What industry is MC2 Therapeutics in?

MC2 Therapeutics's product category is Topical dermatology pharmaceuticals. Its primary akta.pro industry code is HLAIACAL, Dermatology Specialty Pharmaceuticals, with a secondary code of HLAIAAAK, Dermatology & Aesthetics Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2844.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Financial PostKnight Therapeutics Announces Launch of WYNZORA® in CanadaKnight Therapeutics has launched WYNZORA® in Canada following approval from Health Canada. The product, developed by MC2 Therapeutics, is indicated for the treatment of plaque psoriasis in adults based on positive results from phase 3 clinical trials.GlobeNewswireKnight Therapeutics Announces Health Canada Approval for WYNZORA® to Treat Psoriasis VulgarisKnight Therapeutics Inc. announced that Health Canada has approved WYNZORA®, a topical cream combining calcipotriol and betamethasone dipropionate for treating psoriasis vulgaris in adults and adolescents aged 12-17 years. The approval expands Knight's dermatology portfolio following its June 2025 acquisition of Paladin Pharma Inc., which had previously secured Canadian commercialization rights through a license agreement with MC2 Therapeutics. WYNZORA® was developed using MC2's proprietary PAD Technology™ and has demonstrated superior efficacy compared to vehicle in clinical trials while being non-inferior to existing CAL/BDP gel treatments.FierceBiotechChutes & Ladders—20-year Novo vet lands first CEO roleThis article is a weekly roundup of leadership changes across the biotechnology and pharmaceutical industries, featuring appointments such as Trine Ahlgreen becoming CEO of MC2 Therapeutics. It also details other executive moves, including Allyson McMillan-Youngblood joining Acadia Pharmaceuticals and Vibha Jawa taking the CSO role at EpiVax. The content aggregates multiple unrelated personnel announcements rather than focusing on a single event.The Pharma LetterMC2 Therapeutics appoints Trine Ahlgreen as new CEODanish privately-held drugmaker MC2 Therapeutics announced the appointment of Trine Ahlgreen as its new chief executive, succeeding founder Simon Weiss. Ahlgreen brings extensive experience in pharmaceutical commercial leadership across Europe, the USA and Japan. The company stated the appointment marks a new chapter in its efforts to unlock the global potential of its commercial asset Wynzora Cream and maximize its PAD Technology drug delivery platform.PR NewswireEndo Announces Agreement for Paladin Pharma to Commercialize Wynzora® Cream in CanadaEndo announced a definitive agreement with MC2 Therapeutics to commercialize Wynzora Cream in Canada through its subsidiary Paladin Pharma. The cream, approved by the FDA in 2020 and launched in Europe in 2022, targets plaque psoriasis. Health Canada approval is required before the Canadian launch.GlobeNewswireMC2 Therapeutics Receives Positive Feedback from FDA pre-IND Meeting and Updates on Indication Expansion StrategyMC2 Therapeutics received positive feedback from an FDA pre-IND meeting for its oral HSP90 inhibitor MC2-32, targeting Hidradenitis Suppurativa. The company expects to file an IND in mid-2025 and plans a Phase 2 trial in Pyoderma Gangrenosum, with topline results for MC2-25 in VLS expected in Q4.GlobeNewswireMC2 Therapeutics to Present at Upcoming ConferencesMC2 Therapeutics announced its leadership will present at upcoming conferences, including the European Life Sciences CEO Forum in Zürich and the TD Cowen Annual Health Care Conference in Boston. The company's pipeline includes two Phase 2 drug candidates, MC2-32 and MC2-25, both oral HSP90 inhibitors with novel mechanisms.GlobeNewswireMC2 Therapeutics Announces Completion of Enrollment in MC2-25 Ph2 Chronic Kidney Disease-associated Pruritus TrialMC2 Therapeutics completed enrollment in its European Phase 2 trial of MC2-25 CKD for chronic kidney disease-associated pruritus, enrolling 111 patients across multiple centers. The trial is double-blinded, placebo-controlled, with 12 weeks of topical treatment, and topline results are expected in Q2 2024.GlobeNewswireMC2 Therapeutics Announces First Patients Enrolled in Phase 2 Proof of Concept Clinical Trial in Vulvar Lichen SclerosusMC2 Therapeutics announced first patient enrollment in a Phase 2 proof-of-concept trial for MC2-25 VLS, a drug candidate for Vulvar Lichen Sclerosus. The trial will recruit 40 patients across Danish centers, with topline results expected in H2 2024. The company aims to provide relief from severe symptoms, as no approved treatments exist.GlobeNewswireMC2 Therapeutics Announces Positive Phase 2a Results of Novel HSP90 Inhibitor for Hidradenitis Suppurativa Presented at EADVMC2 Therapeutics presented positive Phase 2a data for MC2-32, an oral HSP90 inhibitor, in hidradenitis suppurativa at EADV. The 15-patient trial met HiSCR50 in 6 of 10 MC2-32 patients versus 1 of 5 placebo, with HiSCR75 and HiSCR90 also favored. The company plans a Phase 2b trial.